At the time of writing, Immunic Inc [IMUX] stock is trading at $0.93, down -3.36%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IMUX shares have gain 10.90% over the last week, with a monthly amount glided 24.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on November 25, 2024, and set its price target to $10. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $6 on August 27, 2024. SVB Leerink downgraded its rating to a Mkt Perform but $5 remained the price target by the analyst firm on October 21, 2022. In a note dated April 15, 2021, Aegis Capital initiated an Buy rating and provided a target price of $55 on this stock.
For the past year, the stock price of Immunic Inc fluctuated between $0.56 and $2.11. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Immunic Inc [NASDAQ: IMUX] shares were valued at $0.93 at the most recent close of the market. An investor can expect a potential return of 437.63% based on the average IMUX price forecast.
Analyzing the IMUX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -4.7, Equity is -3.27 and Total Capital is 19.89. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Immunic Inc [NASDAQ:IMUX] has a current ratio of 0.74. As well, the Quick Ratio is 0.74, while the Cash Ratio is 0.56.
Transactions by insiders
Recent insider trading involved Nash Duane, Executive Chairman, that happened on Jun 13 ’25 when 20000.0 shares were purchased. President and COO, Tardio Jason completed a deal on Jun 05 ’25 to buy 12512.0 shares. Meanwhile, CEO and Director Vitt Daniel bought 15000.0 shares on Jun 04 ’25.
